HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.
Transl Lung Cancer Res
; 9(5): 2178-2183, 2020 Oct.
Article
in En
| MEDLINE
| ID: mdl-33209639
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Transl Lung Cancer Res
Year:
2020
Document type:
Article
Affiliation country:
Japan